Advanced search
Publication Cover
Leukemia & Lymphoma Volume 25, 1997 - Issue 3-4
Submit an article Journal homepage
178
Views
77
CrossRef citations to date
0
Altmetric
Original Article

Placebo-Controlled phase III Study of lenograstim (Glycosylated recombinant human granulocyte colony-Stimulating factor) in Aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration

Christian Gisselbrecht Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
,
Corinne Haioun Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
,
Eric Lepage Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
,
Yves Bastion Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
,
Hervé Tilly Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
,
André Bosly Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
,
Brigitte Dupriez Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
,
Gerald Marit Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
,
Raoul Herbrecht Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
,
Eric Deconinck Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
,
Jean Pierre Marolleau Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
,
Antoine Yver Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
,
Farida Dabouz-Harrouche Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
,
Bertrand Coiffier Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
&
Felix Reyes Institut d'Hématologie and Département d'Informatique Médicale, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, Paris, France; Service d'Hématologie, Centre Hospitalier Lyon Sud, Pierre Benite, France; Service d'Hématologie, Hôpital Henri Mondor, Paris, France; Service d'Hématologie, Centre Henri Becquerel, Rouen, France; Clinique Universitaire de Mont Godinne, Yvoir, Belgium; Service d'Hématologie, Centre Hospitalier Claude Huriez, Lille, France; Service d'Hématologie, Centre François Magendie, Bordeaux, France; Service d'Hématologie, Hôpital de Hautepierre, Strasbourg, France; Service d'Hématologie, Hôpital Jean Minjoz, Besançon, France; Lahoratoire Chugai-Rhône Poulenc, Antony, France
 show all
Pages 289-300 | Received 29 Jun 1996, Published online: 05 Aug 2009

Citations (77)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Michael Fiegl, Günther G. Steger, Michael Studnicka, Wolfgang Eisterer, Christine Jaeger & Wolfgang Willenbacher. (2013) Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study. Current Medical Research and Opinion 29:5, pages 505-515.
Read now
A.M. Capotorto, L. Pavesi, P. Pedrazzoli, G.A. Da Prada, C. Zamagni, B. Massidda, A. Farris, A. Martoni, G. Lelli & G. Robustelli Della Cuna. (2003) Randomized, Controlled, Multicenter Phase III Trial of Standard-Dose Fluorouracil-Epirubicin- Cyclophosphamide (FEC), Compared with Time-Intensive FEC (FEC-G) and Mitoxantrone-Methotrexate-Mitomycin C (MMM-G) in Metastatic Breast Carcinoma. Journal of Chemotherapy 15:2, pages 184-191.
Read now
Andrew Grigg, Philippe Solal-Celigny, Peter Hoskin, Kerry Taylor & Andrew M. (2003) Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 44:9, pages 1503-1508.
Read now
Fenella Willis & Ruth Pettengell. (2002) Pegfilgrastim. Expert Opinion on Biological Therapy 2:8, pages 985-992.
Read now

Articles from other publishers (73)

Clémence Canton, Olayidé Boussari, Mathieu Boulin, Karine Le Malicot, Julien Taieb, Laetitia Dahan, Anthony Lopez, Come Lepage & Jean-Baptiste Bachet. (2022) Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma. The Oncologist 27:7, pages e571-e579.
Crossref
L. G. Babicheva & S. O. Podvyaznikov. (2021) Prevention of neutropenia as an important factor in successful chemotherapy for head and neck cancer. Head and Neck Tumors (HNT) 11:3, pages 72-82.
Crossref
Qiuji Wu, Qiu Li, Jun Zhang, Zhumei Luo, Jin Zhou, Jing Chen & Yong Luo. (2021) Comparison of Primary and Secondary Prophylaxis Using PEGylated Recombinant Human Granulocyte–Stimulating Factor as a Cost-Effective Measure in Malignant Neoplasms: A Multicenter Retrospective Study. Frontiers in Pharmacology 12.
Crossref
Yong Wang, Lin Chen, Fen Liu, Ning Zhao, Liyao Xu, Biqi Fu & Yong Li. (2019) Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis. Scientific Reports 9:1.
Crossref
Magali Laprise-Lachance, Pierre Lemieux & Jean-Pierre Grégoire. (2018) Risk of pulmonary toxicity of bleomycin and filgrastim. Journal of Oncology Pharmacy Practice 25:7, pages 1638-1644.
Crossref
Hassam Baig, Barbara Somlo, Melissa Eisen, Scott Stryker, Mark Bensink & Phuong K Morrow. (2018) Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level. Journal of Oncology Pharmacy Practice 25:7, pages 1576-1585.
Crossref
Tsun‐Jen Wen, Yu‐Wen Wen, Chun‐Ru Chien, Shao‐Chin Chiang, William Wei‐Yuan Hsu, Li‐Jiuan Shen & Fei‐Yuan Hsiao. (2016) Cost‐effectiveness of granulocyte colony‐stimulating factor prophylaxis in chemotherapy‐induced febrile neutropenia among breast cancer and Non‐Hodgkin's lymphoma patients under Taiwan's national health insurance system. Journal of Evaluation in Clinical Practice 23:2, pages 288-293.
Crossref
Pamala A Pawloski, Avis J Thomas, Sheryl Kane, Gabriela Vazquez-Benitez, Gary R Shapiro & Gary H Lyman. (2017) Predicting neutropenia risk in patients with cancer using electronic data. Journal of the American Medical Informatics Association 24:e1, pages e-e.
Crossref
Li Wang, Onur Baser, Lucie Kutikova, John H. Page & Richard Barron. (2015) The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Supportive Care in Cancer 23:11, pages 3131-3140.
Crossref
Bing-Bing Yang, Phuong Khanh Morrow, Xikun Wu, Michael Moxness & Desmond Padhi. (2015) Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. Cancer Chemotherapy and Pharmacology 75:6, pages 1199-1206.
Crossref
Sibylle Schirm, Christoph Engel, Markus Loeffler & Markus Scholz. (2014) Modelling chemotherapy effects on granulopoiesis. BMC Systems Biology 8:1.
Crossref
Martin Smoragiewicz, Khodadad R. Javaheri, Yaling Yin & Sharlene Gill. (2014) Neutropenia and Relative Dose Intensity on Adjuvant FOLFOX Chemotherapy Are Not Associated with Survival for Resected Colon Cancer. Journal of Gastrointestinal Cancer 45:4, pages 460-465.
Crossref
J.J. Vehreschild, A. Böhme, O.A. Cornely, C. Kahl, M. Karthaus, K.-A. Kreuzer, G. Maschmeyer, S. Mousset, V. Ossendorf, O. Penack, M.J.G.T. Vehreschild & J. Bohlius. (2014) Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Annals of Oncology 25:9, pages 1709-1718.
Crossref
Lee S. Schwartzberg, Mansoor Saleh, Sadie Whittaker & Esteban Abella. (2014) Severe neutropenia and relative dose intensity among patients <65 and ≥65 years with non-Hodgkin’s lymphoma receiving CHOP-based chemotherapy. Supportive Care in Cancer 22:7, pages 1833-1841.
Crossref
Ananth Shankar. 2013. Evidence-Based Pediatric Oncology. Evidence-Based Pediatric Oncology 207 229 .
Bradford R. Hirsch & Gary H. Lyman. (2012) Pharmacoeconomics of the Myeloid Growth Factors. PharmacoEconomics 30:6, pages 497-511.
Crossref
Kelvin K.W. ChanEric SiuMurray D. KrahnKevin ImrieShabbir M.H. Alibhai. (2012) Cost-Utility Analysis of Primary Prophylaxis Versus Secondary Prophylaxis With Granulocyte Colony-Stimulating Factor in Elderly Patients With Diffuse Aggressive Lymphoma Receiving Curative-Intent Chemotherapy. Journal of Clinical Oncology 30:10, pages 1064-1071.
Crossref
Sebastian Giebel, Xavier Thomas, Helene Hallbook, Klaus Geissler, Jean-Michel Boiron, Francoise Huguet, Elisabeth Koller, Ulrich Jaeger, Bengt Smedmyr, Andrzej Hellmann & Jerzy Holowiecki. (2012) The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: A joint analysis of five randomised trials on behalf of the EWALL. European Journal of Cancer 48:3, pages 360-367.
Crossref
Santosh Saraf & Howard Ozer. 2012. Twenty Years of G-CSF. Twenty Years of G-CSF 109 149 .
A. L. Potosky, J. L. Malin, B. Kim, E. A. Chrischilles & J. C. Weeks. (2011) Re: Personalized Medicine and Cancer Supportive Care: Appropriate Use of Colony-Stimulating Factor Support of Chemotherapy. JNCI Journal of the National Cancer Institute 103:24, pages 1899-1901.
Crossref
Katy L Cooper, Jason Madan, Sophie Whyte, Matt D Stevenson & Ron L Akehurst. (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:1.
Crossref
Jason Madan, Matt D. Stevenson, Katy L. Cooper, A.E. Ades, Sophie Whyte & Ron Akehurst. (2011) Consistency between Direct and Indirect Trial Evidence: Is Direct Evidence Always More Reliable?. Value in Health 14:6, pages 953-960.
Crossref
Gillian M. Keating. (2011) Lenograstim. Drugs 71:6, pages 679-707.
Crossref
Hans Wildiers & Marcel Reiser. (2011) Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Critical Reviews in Oncology/Hematology 77:3, pages 221-240.
Crossref
M.S. Aapro, J. Bohlius, D.A. Cameron, Lissandra Dal Lago, J. Peter Donnelly, N. Kearney, G.H. Lyman, R. Pettengell, V.C. Tjan-Heijnen, J. Walewski, Damien C. Weber & C. Zielinski. (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European Journal of Cancer 47:1, pages 8-32.
Crossref
J. Klocker, J. Schumer, M. Kanatschnig, E. P. Forsthuber, R. Likar & D. Geissler. (2010) Very low rates of neutropenic complications and chemotherapy dose modifications in early breast cancer patients receiving adjuvant FEC-100 or TAC and an individualised G-CSF and anti-infective support: results of a retrospective chart review. memo - Magazine of European Medical Oncology 3:3, pages 123-128.
Crossref
C. Falandry, M. Campone, G. Cartron, D. Guerin & G. Freyer. (2010) Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. European Journal of Cancer 46:13, pages 2389-2398.
Crossref
Gary H. LymanDavid C. DaleDebra A. WolffEva CulakovaMarek S. PoniewierskiNicole M. KudererJeffrey Crawford. (2010) Acute Myeloid Leukemia or Myelodysplastic Syndrome in Randomized Controlled Clinical Trials of Cancer Chemotherapy With Granulocyte Colony-Stimulating Factor: A Systematic Review. Journal of Clinical Oncology 28:17, pages 2914-2924.
Crossref
Nicole M. Kuderer. 2011. Hematopoietic Growth Factors in Oncology. Hematopoietic Growth Factors in Oncology 127 143 .
Gary H. Lyman & Nicole M. Kuderer. 2011. Hematopoietic Growth Factors in Oncology. Hematopoietic Growth Factors in Oncology 167 178 .
Ruth Pettengell, Matti Aapro, Ercole Brusamolino, Dolores Caballero, Bertrand Coiffier, Michael Pfreundschuh, Marek Trneny & Jan Walewski. (2009) Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) Guidelines on the Use of Granulocyte Colony-Stimulating Factor (G-CSF) for Lymphoma Care. Clinical Drug Investigation 29:8, pages 491-513.
Crossref
MaryAnn Foote & George Morstyn. 2009. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy 569 580 .
Julia Bohlius, Christine Herbst, Marcel Reiser, Guido Schwarzer & Andreas Engert. (2008) Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database of Systematic Reviews.
Crossref
A R Clamp, W D J Ryder, S Bhattacharya, R Pettengell & J A Radford. (2008) Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma. British Journal of Cancer 99:2, pages 253-258.
Crossref
P. Morel, P. Gaulard, C. Gisselbrecht, C. Ferme, G. Salles, H. Tilly, J. Brière, M.C. Copin, P. Lederlin, O. Hermine, I. Theate, C. Haioun & N. Mounier. (2008) Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. Annals of Oncology 19:3, pages 560-565.
Crossref
Ercole Brusamolino. (2008) Managing the myelotoxicity of CHOP chemotherapy. European Journal of Cancer Supplements 6:2, pages 31-36.
Crossref
Joyce A. O'Shaughnessy. (2007) Management of Febrile Neutropenia and Cardiac Toxicity in the Adjuvant Treatment of Breast Cancer. Clinical Breast Cancer 8, pages S11-S21.
Crossref
Nicole M. Kuderer, David C. Dale, Jeffrey Crawford & Gary H. Lyman. (2007) Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review. Journal of Clinical Oncology 25:21, pages 3158-3167.
Crossref
Daniel Ribeiro, Marlon R. Veldwijk, Axel Benner, Stephanie Laufs, Frederik Wenz, Anthony D. Ho & Stefan Fruehauf. (2007) Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion 47:6, pages 969-980.
Crossref
Delvyn C. CaseJrJr, Christopher E. Desch, Leonard A. Kalman, Piyapong Vongkovit, Raul R. Mena, Moshe Fridman & Barbara Allen. (2007) Community-Based Trial of R-CHOP and Maintenance Rituximab for Intermediate- or High-Grade Non-Hodgkin Lymphoma with First-Cycle Filgrastim for Older Patients. Clinical Lymphoma and Myeloma 7:5, pages 354-360.
Crossref
John A. Glaspy. 2007. Cytokines in the Genesis and Treatment of Cancer. Cytokines in the Genesis and Treatment of Cancer 449 469 .
M.S. Aapro, D.A. Cameron, R. Pettengell, J. Bohlius, J. Crawford, M. Ellis, N. Kearney, G.H. Lyman, V.C. Tjan-Heijnen, J. Walewski, D.C. Weber & C. Zielinski. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer 42:15, pages 2433-2453.
Crossref
Victor Aquino & Eric Sandler. 2006. Pediatric Hematopoietic Stem Cell Transplantation. Pediatric Hematopoietic Stem Cell Transplantation 1 26 .
Thomas J. Smith, James Khatcheressian, Gary H. Lyman, Howard Ozer, James O. Armitage, Lodovico Balducci, Charles L. Bennett, Scott B. Cantor, Jeffrey Crawford, Scott J. Cross, George Demetri, Christopher E. Desch, Philip A. Pizzo, Charles A. Schiffer, Lee Schwartzberg, Mark R. Somerfield, George Somlo, James C. Wade, James L. Wade, Rodger J. Winn, Antoinette J. Wozniak & Antonio C. Wolff. (2006) 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. Journal of Clinical Oncology 24:19, pages 3187-3205.
Crossref
Gary H. Lyman & Nicole M. Kuderer. (2005) Moving Beyond Febrile Neutropenia. Supportive Cancer Therapy 2:2, pages 95-97.
Crossref
G.H. Lyman & N.M. Kuderer. (2004) The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Critical Reviews in Oncology/Hematology 50:2, pages 129-146.
Crossref
A Hackshaw, J Sweetenham & A Knight. (2004) Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?. British Journal of Cancer 90:7, pages 1302-1305.
Crossref
Gary H. Lyman & Nicole M. Kuderer. 2004. Hematopoietic Growth Factors in Oncology. Hematopoietic Growth Factors in Oncology 409 443 .
Gary H. Lyman, Nicole Kuderer, Olayemi Agboola & Lodovico Balducci. (2017) Evidence-Based Use of Colony-Stimulating Factors in Elderly Cancer Patients. Cancer Control 10:6, pages 487-499.
Crossref
R. Paridaens, G.H. Lyman, R. Leonard, J. Crawford, A. Bosly, M. Constenla, C. Jackisch, R. Pettengell & T. Szucs. (2003) Delivering optimal adjuvant chemotherapy in primary breast cancer: the role of rHuG-CSF. European Journal of Cancer Supplements 1:9, pages 1-12.
Crossref
Gary H. Lyman & Nicole M. Kuderer. (2003) Epidemiology of Febrile Neutropenia. Supportive Cancer Therapy 1:1, pages 23-35.
Crossref
Artur Bauhofer, Bjirn Tischer, Martin Middeke, Ulrike Plaul, Wilfried Lorenz & Alexander Torossian. (2003) The Genetic Background of Hypertensive, Septic Rats Determines Outcome Improvement With Antibiotic and G-CSF Prophylaxis. Shock 20:4, pages 326-331.
Crossref
Antonio Pagliuca, Patrick A. Carrington, Ruth Pettengell, Simon Rule & Jane Keidan. (2003) Guidelines on the use of colony-stimulating factors in haematological malignancies. British Journal of Haematology 123:1, pages 22-33.
Crossref
Julia Bohlius, Marcel Reiser, Guido Schwarzer & Andreas Engert. (2003) Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. British Journal of Haematology 122:3, pages 413-423.
Crossref
Mary V. RellingJames M. BoyettJavier G. BlancoSusana RaimondiFrederick G. BehmJohn T. SandlundGaston K. RiveraLarry E. KunWilliam E. EvansChing-Hon Pui. (2003) Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101:10, pages 3862-3867.
Crossref
J.M. VoseM. CrumpH. LazarusC. EmmanouilidesD. SchenkeinJ. MooreS. FrankelI. FlinnW. LovelaceJ. HackettB.C. Liang. (2003) Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma. Journal of Clinical Oncology 21:3, pages 514-519.
Crossref
Maryann Foote, Bertrand C. Liang, Jeffrey Crawford, Frankie A. Holmes, Michael Green, Frankie A. Holmes, Michael Green & George Morstyn. 2003. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy 543 555 .
A Bauhofer, B Stinner, F Kohlert, B Reckzeh, W Lorenz & I Celik. (2002) Granulocyte colony-stimulating factor but not peritoneal lavage increases survival rate after experimental abdominal contamination and infection. British Journal of Surgery 89:11, pages 1457-1464.
Crossref
Charles Dumontet, Nicolas Mounier, Jean Nicolas Munck, André Bosly, Frank Morschauser, Daniele Simon, Gérald Marit, Olivier Casasnovas, Oumédaly Reman, Thierry Molina, Felix Reyes & Bertrand Coiffier. (2002) Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. British Journal of Haematology 118:1, pages 210-217.
Crossref
Christian GisselbrechtEric LepageThierry MolinaBruno QuesnelGeorges FilletPierre LederlinBertrand CoiffierHervé TillyJean GabarreFrancoise GuilminOlivier HermineFélix Reyes. (2002) Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma. Journal of Clinical Oncology 20:10, pages 2472-2479.
Crossref
Takao Hidaka, Masaki Fujimura, Akitoshi Nakashima, Subaru Higuma, Naoko Yamagishi, Hiroshi Tsuda, Masatoshi Sakai & Shigeru Saito. (2005) Macrophage Colony‐stimulating Factor (M‐CSF) Prevents Infectious Death Induced by Chemotherapy in Mice, While Granulocyte‐CSF Does Not. Japanese Journal of Cancer Research 93:4, pages 426-435.
Crossref
Milka Maravic, Isabelle Cojean-Zelek, Pascal Chazerain & Jean-Marc Ziza. (2002) Manifestations rhumatologiques des anticancéreux. Revue du Rhumatisme 69:4, pages 424-433.
Crossref
Gary H Lyman, Nicole M Kuderer & Benjamin Djulbegovic. (2002) Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. The American Journal of Medicine 112:5, pages 406-411.
Crossref
C. PatteA. LaplancheA. I. BertozziA. BaruchelD. FrappazC. SchmittF. MechinaudB. NelkenP. BoutardJ. Michon. (2002) Granulocyte Colony-Stimulating Factor in Induction Treatment of Children With Non-Hodgkin’s Lymphoma: A Randomized Study of the French Society of Pediatric Oncology. Journal of Clinical Oncology 20:2, pages 441-448.
Crossref
Jeff Schriber. (2002) Treatment of Aggressive Non-Hodgkin??s Lymphoma with Chemotherapy in Combination with Filgrastim. Drugs 62:Supplement 1, pages 33-46.
Crossref
David C. Dale. (2002) Colony-Stimulating Factors for the Management of Neutropenia in Cancer Patients. Drugs 62:Supplement 1, pages 1-15.
Crossref
&NA;. (2001) Lenograstim shows potential in a wide range of neutropenic and other indications. Drugs & Therapy Perspectives 17:1, pages 1-5.
Crossref
Eileen JohnstonJeffrey CrawfordSusan BlackwellToni BjurstromPamela LockbaumLorin RoskosBing-Bing YangSheila GardnerMary Ann Miller-MessanaDebra ShoemakerJennifer GarstGisela Schwab. (2000) Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving Chemotherapy. Journal of Clinical Oncology 18:13, pages 2522-2528.
Crossref
Hervé TillyNicolas MounierPierre LederlinJosette BrièreBrigitte DupriezCatherine SebbanAndré BoslyPierre BironCatherine NouvelRaoul HerbrechtDominique BordessouleBertrand Coiffier. (2000) Randomized Comparison of ACVBP and m-BACOD in the Treatment of Patients With Low-Risk Aggressive Lymphoma: The LNH87-1 Study. Journal of Clinical Oncology 18:6, pages 1309-1315.
Crossref
Marin H. Kollef. (1999) EPIDEMIOLOGY AND RISK FACTORS FOR NOSOCOMIAL PNUEMONIA. Clinics in Chest Medicine 20:3, pages 653-670.
Crossref
J-L D Klein, J D Roberts, M D George, J Kurtzberg, P Breton, J-C Chermann & K Olden. (1999) Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity. British Journal of Cancer 80:1-2, pages 87-95.
Crossref
E. M. Johnston & J. Crawford. 1999. Oncologic Therapies. Oncologic Therapies 1077 1098 .
Henrik van Deventer & Thomas Shea. 1999. Clinical Applications of Cytokines and Growth Factors. Clinical Applications of Cytokines and Growth Factors 279 299 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.